Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01981187
Title LGX818 for Patients With BRAFV600 Mutated Tumors
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

hematologic cancer

Advanced Solid Tumor

Therapies

Encorafenib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST